Keywords: gilead, pays, 5b, premium, mycogen, get, heart

Gilead pays $2.5B, a 50% premium, for Mycogen to get heart drug candidates

Article | 09 October 2006

Print This

Gilead Sciences has announced plans to acquire fellow USA-based Myogen in order to gain control of the latter's portfolio of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in